News | November 14, 2023
Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’
Yesafili, received marketing authorization approval from the European Commission for the European Union
Yesafili, received marketing authorization approval from the European Commission for the European Union
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
European operations' revenue grew 58.4% to Rs 599.7 crore
General Medicine grows 5% and Vaccines 10% led by Shingrix
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
Total transaction value of the divestment is Rs. 3,660 million
Lack of technology transfer stands out as a formidable barrier
Subscribe To Our Newsletter & Stay Updated
